Edition:
India

Pfizer Inc (PFE.N)

PFE.N on New York Stock Exchange

36.82USD
23 Jan 2018
Change (% chg)

$-0.11 (-0.30%)
Prev Close
$36.93
Open
$36.77
Day's High
$37.07
Day's Low
$36.54
Volume
5,262,439
Avg. Vol
5,217,307
52-wk High
$37.37
52-wk Low
$30.90

Select another date:

U.S. appeals court upholds ruling invalidating J&J patent on Remicade

A U.S. appeals court on Tuesday upheld a ruling that invalidated a crucial Johnson & Johnson patent on its blockbuster rheumatoid arthritis drug Remicade, limiting J&J’s ability to seek damages from Pfizer Inc over its launch of a lower-cost version of the drug.

U.S. appeals court upholds ruling invalidating J&J patent on Remicade

A U.S. appeals court on Tuesday upheld a ruling that invalidated a crucial Johnson & Johnson patent on its blockbuster rheumatoid arthritis drug Remicade, limiting J&J’s ability to seek damages from Pfizer Inc over its launch of a lower-cost version of the drug.

UPDATE 2-U.S. appeals court upholds ruling invalidating J&J patent on Remicade

Jan 23 A U.S. appeals court on Tuesday upheld a ruling that invalidated a crucial Johnson & Johnson patent on its blockbuster rheumatoid arthritis drug Remicade, limiting J&J’s ability to seek damages from Pfizer Inc over its launch of a lower-cost version of the drug.

BRIEF-Kite Announces Clinical Collaboration With Pfizer

* KITE ANNOUNCES CLINICAL COLLABORATION TO EVALUATE INVESTIGATIONAL COMBINATION OF YESCARTA™ (AXICABTAGENE CILOLEUCEL) AND PFIZER’S UTOMILUMAB IN LARGE B-CELL LYMPHOMA

BRIEF-Foundation Medicine, Pfizer Announce Partnership To Develop Companion Diagnostics For Pfizer’S Oncology Portfolio

* FOUNDATION MEDICINE AND PFIZER ANNOUNCE BROAD PARTNERSHIP TO DEVELOP COMPANION DIAGNOSTICS FOR PFIZER’S ONCOLOGY PORTFOLIO

BRIEF-Novartis poaches Pfizer oncology head Elizabeth Barrett

* Elizabeth (Liz) Barrett, currently Global President Oncology at Pfizer, Inc., has been appointed CEO Novartis Oncology and a member of the Executive Committee of Novartis, effective February 1, 2018

BRIEF-Basilea Announces Completion Of License Agreement Extension With Pfizer

* BASILEA ANNOUNCES COMPLETION OF THE LICENSE AGREEMENT EXTENSION WITH PFIZER FOR ANTIFUNGAL CRESEMBA FOR CHINA AND ASIA PACIFIC Source text for Eikon: Further company coverage: (Gdynia Newsroom)

GSK CEO says looking at Pfizer consumer business, but not a priority

GlaxoSmithKline's new chief executive said on Tuesday that the British drugmaker would have a look at Pfizer Inc's consumer products business, but would not overpay for the asset.

GSK CEO says looking at Pfizer consumer business, but not a priority

GlaxoSmithKline's new chief executive said on Tuesday that the British drugmaker would have a look at Pfizer Inc's consumer products business, but would not overpay for the asset.

GSK CEO says looking at Pfizer consumer business, but not a priority

Jan 9 GlaxoSmithKline's new chief executive said on Tuesday that the British drugmaker would have a look at Pfizer Inc's consumer products business, but would not overpay for the asset.

Select another date: